Liraglutide - HEC Pharm
Latest Information Update: 05 Nov 2015
At a glance
- Originator HEC Pharm
- Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Obesity therapies; Pancreatic hormones
- Mechanism of Action Glucagon like peptide 1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 05 Nov 2015 Preclinical trials for Diabetes mellitus in China (route of administration) (HEC Pharma pipeline, October 2015)